|1.||Joukhadar, Christian: 4 articles (01/2011 - 01/2002)|
|2.||Müller, Markus: 3 articles (02/2005 - 01/2002)|
|3.||Zeitlinger, Markus: 2 articles (10/2012 - 02/2005)|
|4.||Sauermann, Robert: 2 articles (10/2012 - 02/2005)|
|5.||Rajput, Neetu: 2 articles (11/2008 - 03/2007)|
|6.||Delle-Karth, Georg: 2 articles (02/2005 - 07/2002)|
|7.||Heinz, G: 2 articles (06/2003 - 04/2000)|
|8.||Georgopoulos, A: 2 articles (06/2003 - 02/2000)|
|9.||Kreischitz, Nicole: 2 articles (07/2002 - 01/2002)|
|10.||Klein, Nikolas: 2 articles (07/2002 - 01/2002)|
01/15/2002 - "The present data also corroborate the use of cefpirome as a valuable agent in the treatment of lung infections with most extracellular bacteria."
11/01/2000 - "These results suggest that cefpirome sulphate is effective in the treatment of obstetric and gynaecological infections and has a good side-effect profile."
11/01/2000 - "Clinical study of cefpirome sulphate in obstetric and gynaecological infections."
07/01/1998 - "Prior studies of cefpirome therapy for infections caused by Streptococcus spp. were successful, and recent expanded in vitro investigations profess a future for expanded use of cefpirome to treat infections produced by several Gram-positive species."
04/01/1992 - "Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. "
04/01/1992 - "Cefpirome administered as 1 or 2g twice daily was a well tolerated, effective agent for the treatment of severe sepsis in hospitalized patients."
07/01/1999 - "A multicentre trial was performed to study the efficacy and safety of cefpirome 2 g twice daily in the treatment of sepsis. "
07/01/2002 - "Thus, cefpirome exhibits a tissue pharmacokinetic profile, which seems to be particularly valuable for the empirical therapy of patients with sepsis."
07/01/2002 - "Cefpirome concentrations reached in tissue interstitium and plasma exceeded minimal inhibitory concentrations of most clinically relevant pathogens in patients with sepsis. "
07/01/2002 - "Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis."
|3.||Bacterial Infections (Bacterial Infection)
03/01/1992 - "The results, for safety and pharmacokinetics, show that cefpirome can be expected to have excellent clinical efficacy for bacterial infections."
07/01/2002 - "Thus, the present study aimed at describing penetration properties of cefpirome to the target site of many bacterial infections, which is the extracellular space fluid of soft tissues. "
08/01/1991 - "Mean cefpirome clearance in patients with Clcr greater than 80 mL/min was 107.6 mL/min. In conclusion, these data on cefpirome clearance obtained after multiple dose treatment of patients with presumed bacterial infection are consistent with data previously obtained from single dose volunteer studies and support the currently recommended dose regimens. "
03/01/2007 - "Based on the pharmacokinetic parameters we obtained, an appropriate intravenous cefpirome dosage regimen for treating cefpiromesensitive bacteria in buffalo calves would be 8.0 mg/kg repeated at 12 h intervals for 5 days, or until persistence of the bacterial infection occurred."
01/01/1996 - "The clinical efficacy and tolerance of cefpirome were estimated in the treatment of patients with bacterial infection of the respiratory tract. "
|4.||Renal Insufficiency (Renal Failure)
04/01/2000 - "Cefpirome is a new semisynthetic cephalosporin, primarily eliminated by the kidneys, that requires dosage adjustment in patients with kidney failure. "
12/01/1996 - "Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. "
10/01/1993 - "Cefpirome is eliminated primarily by renal excretion, compelling dosage reduction in kidney failure. "
08/01/1991 - "Mean cefpirome clearance in patients with Clcr 18-50 mL/min was 42.7 mL/min, which is very similar to the figure of 43.5 mL/min reported in a single dose volunteer study in patients with renal failure. "
12/01/1999 - "Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration."
03/01/1994 - "The conditions for the emergence of resistance to cefpirome and ceftazidime were studied in rabbits with experimental aortic endocarditis due to Pseudomonas aeruginosa. "
03/01/1994 - "Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa."
04/01/1992 - "Cefpirome was the most effective cephalosporin as therapy for methicillin-susceptible Staphylococcus aureus experimental endocarditis. "
08/01/1995 - "The efficacy of cefazolin or cefpirome alone or combined with rifampin was compared with that of vancomycin alone or combined with rifampin in an experimental model of methicillin-resistant, beta-lactamase-producing, coagulase-negative staphylococcal endocarditis. "
11/01/1993 - "The efficacy of cefepime, a new broad-spectrum cephalosporin, was compared with those of cefpirome, ceftazidime, vancomycin, imipenem-cilastatin and penicillin G in a rat model of endocarditis caused by a methicillin-susceptible strain of Staphylococcus aureus. "
|1.||cefpirome (HR 810)
|9.||Anti-Bacterial Agents (Antibiotics)
|10.||Cefoperazone (Cefoperazone Sodium)
|1.||Cardiopulmonary Resuscitation (CPR)
|5.||Intensive Care (Surgical Intensive Care)